769 related articles for article (PubMed ID: 27762654)
1. Effect of increasing radiation dose on pathologic complete response in rectal cancer patients treated with neoadjuvant chemoradiation therapy.
Hall MD; Schultheiss TE; Smith DD; Fakih MG; Wong JY; Chen YJ
Acta Oncol; 2016 Dec; 55(12):1392-1399. PubMed ID: 27762654
[TBL] [Abstract][Full Text] [Related]
2. Impact of Total Lymph Node Count on Staging and Survival After Neoadjuvant Chemoradiation Therapy for Rectal Cancer.
Hall MD; Schultheiss TE; Smith DD; Fakih MG; Kim J; Wong JY; Chen YJ
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S580-7. PubMed ID: 25956577
[TBL] [Abstract][Full Text] [Related]
3. Comparison of pathological complete response rates after neoadjuvant short-course radiotherapy or chemoradiation followed by delayed surgery in locally advanced rectal cancer.
Hoendervangers S; Couwenberg AM; Intven MPW; van Grevenstein WMU; Verkooijen HM
Eur J Surg Oncol; 2018 Jul; 44(7):1013-1017. PubMed ID: 29650419
[TBL] [Abstract][Full Text] [Related]
4. Recurrence rates and prognostic factors in ypN0 rectal cancer after neoadjuvant chemoradiation and total mesorectal excision.
Govindarajan A; Reidy D; Weiser MR; Paty PB; Temple LK; Guillem JG; Saltz LB; Wong WD; Nash GM
Ann Surg Oncol; 2011 Dec; 18(13):3666-72. PubMed ID: 21590450
[TBL] [Abstract][Full Text] [Related]
5. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.
Shanmugan S; Arrangoiz R; Nitzkorski JR; Yu JQ; Li T; Cooper H; Konski A; Farma JM; Sigurdson ER
Ann Surg Oncol; 2012 Jul; 19(7):2178-85. PubMed ID: 22395978
[TBL] [Abstract][Full Text] [Related]
6. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival.
Kim NK; Baik SH; Seong JS; Kim H; Roh JK; Lee KY; Sohn SK; Cho CH
Ann Surg; 2006 Dec; 244(6):1024-30. PubMed ID: 17122629
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment Tumor Thickness as a Predictor of Pathologic Complete Response to Neoadjuvant Chemoradiation Therapy for Stage II/III Rectal Adenocarcinoma.
Xu B; Chen Y; Guo Y; Zhou D; Yue Z; Duan Q; Yang Y; Guan G; Chi P; Lin C
Am J Clin Oncol; 2018 Jun; 41(6):601-606. PubMed ID: 27672742
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery for locally advanced rectal cancer: a single-institution experience.
Tseng MSF; Zheng H; Ng IWS; Leong YH; Leong CN; Yong WP; Cheong WK; Tey JCS
Singapore Med J; 2018 Jun; 59(6):305-310. PubMed ID: 29167909
[TBL] [Abstract][Full Text] [Related]
9. Less than 12 nodes in the surgical specimen after total mesorectal excision following neoadjuvant chemoradiation: it means more than you think!
de Campos-Lobato LF; Stocchi L; de Sousa JB; Buta M; Lavery IC; Fazio VW; Dietz DW; Kalady MF
Ann Surg Oncol; 2013 Oct; 20(11):3398-406. PubMed ID: 23812804
[TBL] [Abstract][Full Text] [Related]
10. Combination of differentiation and T stage can predict unresponsiveness to neoadjuvant therapy for rectal cancer.
Qiu HZ; Wu B; Xiao Y; Lin GL
Colorectal Dis; 2011 Dec; 13(12):1353-60. PubMed ID: 21689282
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of patients with complete pathologic response after neoadjuvant chemoradiation for cT3 rectal cancer: implications for local excision surgical strategies.
Belluco C; De Paoli A; Canzonieri V; Sigon R; Fornasarig M; Buonadonna A; Boz G; Innocente R; Perin T; Cossaro M; Polesel J; De Marchi F
Ann Surg Oncol; 2011 Dec; 18(13):3686-93. PubMed ID: 21691880
[TBL] [Abstract][Full Text] [Related]
12. Improved outcomes for rectal cancer in the era of preoperative chemoradiation and tailored mesorectal excision: a series of 338 consecutive cases.
Pacelli F; Sanchez AM; Covino M; Tortorelli AP; Bossola M; Valentini V; Gambacorta MA; Doglietto GB
Am Surg; 2013 Feb; 79(2):151-61. PubMed ID: 23336654
[TBL] [Abstract][Full Text] [Related]
13. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study.
Fernández-Martos C; Pericay C; Aparicio J; Salud A; Safont M; Massuti B; Vera R; Escudero P; Maurel J; Marcuello E; Mengual JL; Saigi E; Estevan R; Mira M; Polo S; Hernandez A; Gallen M; Arias F; Serra J; Alonso V
J Clin Oncol; 2010 Feb; 28(5):859-65. PubMed ID: 20065174
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemoradiation versus hyperfractionated accelerated radiotherapy in locally advanced rectal cancer.
Ceelen W; Boterberg T; Pattyn P; van Eijkeren M; Gillardin JM; Demetter P; Smeets P; Van Damme N; Monsaert E; Peeters M
Ann Surg Oncol; 2007 Feb; 14(2):424-31. PubMed ID: 17096057
[TBL] [Abstract][Full Text] [Related]
15. Delaying surgery after neoadjuvant chemoradiotherapy in rectal cancer has no influence in surgical approach or short-term clinical outcomes.
Figueiredo N; Panteleimonitis S; Popeskou S; Cunha JF; Qureshi T; Beets GL; Heald RJ; Parvaiz A
Eur J Surg Oncol; 2018 Apr; 44(4):484-489. PubMed ID: 29398323
[TBL] [Abstract][Full Text] [Related]
16. Tumor response after long interval comparing 5x5Gy radiation therapy with chemoradiation therapy in rectal cancer patients.
Rombouts AJM; Hugen N; Verhoeven RHA; Elferink MAG; Poortmans PMP; Nagtegaal ID; de Wilt JHW
Eur J Surg Oncol; 2018 Jul; 44(7):1018-1024. PubMed ID: 29678303
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Outcome of Rectal Cancer With Clinically (EUS/MRI) Metastatic Mesorectal Lymph Nodes Treated by Neoadjuvant Chemoradiation: Role of Organ Preservation Strategies in Relation to Pathologic Response.
Belluco C; Forlin M; Olivieri M; Cannizzaro R; Canzonieri V; Buonadonna A; Bidoli E; Matrone F; Bertola G; De Paoli A
Ann Surg Oncol; 2016 Dec; 23(13):4302-4309. PubMed ID: 27489059
[TBL] [Abstract][Full Text] [Related]
18. Comparative Outcomes of Neoadjuvant Treatment Prior to Total Mesorectal Excision and Total Mesorectal Excision Alone in Selected Stage II/III Low and Mid Rectal Cancer.
Kulu Y; Tarantino I; Billeter AT; Diener MK; Schmidt T; Büchler MW; Ulrich A
Ann Surg Oncol; 2016 Jan; 23(1):106-13. PubMed ID: 26305025
[TBL] [Abstract][Full Text] [Related]
19. Downstaging without complete pathologic response after neoadjuvant treatment improves cancer outcomes for cIII but not cII rectal cancers.
de Campos-Lobato LF; Stocchi L; da Luz Moreira A; Kalady MF; Geisler D; Dietz D; Lavery IC; Remzi FH; Fazio VW
Ann Surg Oncol; 2010 Jul; 17(7):1758-66. PubMed ID: 20131015
[TBL] [Abstract][Full Text] [Related]
20. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
